Abstracts

DIVERGENT AND SELF-REACTIVE IMMUNE RESPONSES IN THE CNS OF COVID-19 PATIENTS

One third of COVID-19 patients develop significant neurological symptoms, yet SARS-CoV-2 is rarely detected in central nervous system (CNS) tissue, suggesting a potential role for parainfectious processes, including neuroimmune responses. We examined immune parameters in CSF and blood samples from a cohort of hospitalized patients with COVID-19 and significant neurological complications (n=6), compared to SARS-CoV-2…

COVID-19 IMPACT ON INDEX TESTING SERVICES IN 5 HIGH HIV PREVALENCE INDIAN DISTRICTS

Routine HIV testing for partners and children of PLHIV (e.g., index testing) is a key component of HIV prevention. Anecdotal information suggests that the COVID-19 pandemic’s lockdowns and subsequent economic and mobility restrictions have impacted HIV testing programs; however, there is limited empirical data demonstrating this. Beginning in Oct 2019, we initiated index testing services…

IMPACT OF VAGINAL STIs ON bNAb PROTECTION IN MACAQUES

Broadly neutralizing antibodies (bNAbs) confer durable protection in macaques against repeated mucosal SHIV challenges and are being evaluated clinically for pre-exposure prophylaxis (PrEP). In a prior study, bNAb 10-1074 provided durable protection against repeated vaginal SHIV challenge in macaques where the plasma concentration at breakthrough was 0.1?g ml-1. Sexually transmitted infections (STIs) increase mucosal HIV…

PHASE 1 PK, SAFETY, AND ACCEPTABILITY STUDY OF 3-MONTH DAPIVIRINE VAGINAL RINGS

Vaginal rings (VRs) are a promising approach to long-acting HIV prevention. Extended duration VRs may reduce user burden and cost, streamline follow-up, and encourage adherence. We evaluated the safety, pharmacokinetics, adherence, and acceptability of two 3-month dapivirine (DPV) VRs compared with the monthly DPV VR. MTN-036/IPM-047 enrolled 49 HIV-negative participants into a Phase 1, multi-site,…

COST-EFFECTIVENESS OF LONG-ACTING PrEP AMONG MSM/TGW IN THE US

HIV Prevention Trials Network (HPTN) 083 demonstrated superior efficacy of long-acting injectable cabotegravir (CAB-LA) compared to oral tenofovir disoproxil fumarate/emtricitabine (F/TDF) for HIV pre-exposure prophylaxis (PrEP). CAB-LA cost may be higher than that of generic F/TDF. We projected the clinical benefit of CAB-LA vs. F/TDF and estimated the cost at which CAB-LA would be cost-effective.…